• Explore /
  • Poster
  • / Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

National Cancer Center Hospital East, Chiba, Japan

Kohei Shitara , Toshihiko Doi , Hisashi Hosaka , Peter C. Thuss-Patience , Armando Santoro , Paula Jiménez-Fonseca , FEDERICO LONGO , Ozgur Ozyilkan , Irfan Cicin , David Park , Mohamedtaki Abdulaziz Tejani , Aziz Zaanan , Domenico Bilancia , Carles Pericay , Mustafa Ozguroglu , Maria Alsina , Lukas Makris , Sandra McGuigan , David H. Ilson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02500043

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4037)

DOI

10.1200/JCO.2019.37.15_suppl.4037

Abstract #

4037

Poster Bd #

142

Abstract Disclosures

Similar Posters

First Author: Josep Tabernero

First Author: Ilya Tsimafeyeu

First Author: Maria Alsina

First Author: Wasat Mansoor